GBI SOURCE is a global pharmaceutical database covering the entire product lifecycle. It enables professionals and executives across the life sciences industry to gain a 360-degree view of the global pharmaceutical landscape through industry news worldwide, policy analysis, competitive intelligence, and analytical tools built on a standardized data framework, supporting data-driven decision-making.
Identifying Strategic R&D Opportunities
With numerous disease areas, therapeutic targets, and treatment modalities to evaluate, companies often lack the market and competitive intelligence needed to prioritize R&D investments and guide strategic planning.
Keeping Pace with the Competitive Landscape
Competitor intelligence—including pipeline progress, clinical trial results, indication expansion, licensing activity, and strategic partnerships—is often fragmented across multiple sources, limiting visibility into competitive developments.
Navigating Market Access
As products move closer to market, companies must assess market potential, reimbursement environments, competitive positioning, and evolving policy landscapes. Without integrated market intelligence, market access strategies carry greater uncertainty.
GBI SOURCE is a global pharmaceutical intelligence platform spanning the entire product life cycle, from preclinical research through post-market activities. Powered by AI-driven data integration and analytics, it delivers accurate drug development intelligence, comprehensive market access data, and timely industry insights, enabling faster, more informed research and strategic decision-making.
Track tens of thousands of drug development programs worldwide, spanning the entire R&D lifecycle from preclinical research through clinical development and regulatory filing. Connected data—including clinical trials, study results, licensing deals, sales performance, and industry news—provides a complete view of each pipeline asset, enabling faster and more informed research.
Analyze more than 6 million tender records and nearly 600,000 historical NRDL listings covering every province and municipality in China. Additional data on commercial insurance schemes, including Huiminbao, and Patient Assistance Programs (PAPs) provides a comprehensive view of market access pathways and supports commercialization planning.
Monitor global pharmaceutical news, regulatory developments, and market activity. Expert analysts curate daily news briefings and in-depth reports covering drug development, licensing and financing transactions, market performance, and policy developments, helping users identify and respond to emerging industry trends.
GBI Health unites global pharmaceutical data, AI capabilities and industry expertise to deliver future-ready solutions across the entire product lifecycle.
Contact Us
